ReviewFrontiers in immunology2026
ILC plasticity in intestinal immune barrier remodeling: current evidence and therapeutic implications for inflammatory bowel disease.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a group of chronic gastrointestinal inflammatory diseases characterized by persistent mucosal inflammation and intestinal immune barrier dysfunction. Innate lymphoid cells (ILCs) are key regulators of mucosal immunity; however, the contribution of their context-dependent plasticity to IBD-associated immune barrier remodeling remains incompletely defined. This narrative review summarizes the intestinal distribution and functional specialization of ILC subsets, their dysregulation in the IBD microenvironment, and the molecular signals that regulate ILC plasticity. Current evidence most strongly supports an ILC3-to-ILC1 transition in CD, whereas direct evidence for defined directional ILC plasticity in UC and for ILC2 lineage conversion in intestinal IBD remains limited. We also discuss the context-dependent roles of ILC2s in epithelial repair, inflammation, and fibrosis, as well as the functional reprogramming of ILC3s from barrier-protective to potentially pathogenic states. In addition, this review summarizes the cytokine, transcriptional, epigenetic, and metabolic mechanisms associated with ILC fate remodeling and discusses potential therapeutic strategies targeting these pathways. Overall, ILC plasticity may represent a disease- and tissue-specific mechanism contributing to intestinal immune barrier remodeling, although its causal role and therapeutic relevance require further validation in human IBD. These findings provide a framework for developing more precisely stratified and context-dependent therapeutic approaches for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.